207 related articles for article (PubMed ID: 17699296)
1. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience.
Vo AA; Cam V; Toyoda M; Puliyanda DP; Lukovsky M; Bunnapradist S; Peng A; Yang K; Jordan SC
Clin J Am Soc Nephrol; 2006 Jul; 1(4):844-52. PubMed ID: 17699296
[TBL] [Abstract][Full Text] [Related]
2. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation.
Chapman SA; Gilkerson KL; Davin TD; Pritzker MR
Ann Pharmacother; 2004 Dec; 38(12):2059-67. PubMed ID: 15536143
[TBL] [Abstract][Full Text] [Related]
3. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy.
Daphnis E; Stylianou K; Alexandrakis M; Xylouri I; Vardaki E; Stratigis S; Kyriazis J
Nephron Clin Pract; 2007; 106(4):c143-8. PubMed ID: 17596722
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion.
Welles CC; Tambra S; Lafayette RA
Am J Kidney Dis; 2010 Jan; 55(1):148-51. PubMed ID: 19628320
[TBL] [Abstract][Full Text] [Related]
6. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
7. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
[TBL] [Abstract][Full Text] [Related]
8. [Acute kidney failure secondary to intravenous immunoglobulin administration. 4 cases and review of the literature].
Decocq G; de Cagny B; Andréjak M; Desablens B
Therapie; 1996; 51(5):516-26. PubMed ID: 9138386
[TBL] [Abstract][Full Text] [Related]
9. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
10. [Adverse events in 1395 infusions with different intravenous gammaglobulin products].
Malbrán A; Larrauri B; Juri MC; Fernández Romero DS
Medicina (B Aires); 2013; 73(5):433-7. PubMed ID: 24152399
[TBL] [Abstract][Full Text] [Related]
11. Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
Barsheshet A; Marai I; Appel S; Zimlichman E
Ann N Y Acad Sci; 2007 Sep; 1110():315-8. PubMed ID: 17911446
[TBL] [Abstract][Full Text] [Related]
12. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy.
Ahsan N
J Nephrol; 1998; 11(3):157-61. PubMed ID: 9650125
[TBL] [Abstract][Full Text] [Related]
13. Proposed relationship between intravenous immunoglobulin and thrombosis in renal transplant recipients.
Duronio A; Bajjoka I; Hsaiky L; Parasuraman R
Ann Pharmacother; 2007 Feb; 41(2):354-8. PubMed ID: 17264157
[TBL] [Abstract][Full Text] [Related]
14. [Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].
Maroto Hernando M; Soler Palacín P; Martin Nalda N; Oliveras Arenas M; Español Boren T; Figueras Nadal C
An Pediatr (Barc); 2009 Feb; 70(2):111-9. PubMed ID: 19217565
[TBL] [Abstract][Full Text] [Related]
15. Myocardial infarction during intravenous immunoglobulin infusion in a 65-year-old man with common variable immunodeficiency and subsequent successful repeated administration.
Davé S; Hagan J
Ann Allergy Asthma Immunol; 2007 Dec; 99(6):567-70. PubMed ID: 18219840
[TBL] [Abstract][Full Text] [Related]
16. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
17. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
19. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
Rigas M; Tandan R; Sterling RJ
J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
[TBL] [Abstract][Full Text] [Related]
20. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
